LEADER 04554nam 2200637Ia 450 001 9910831047203321 005 20170809163458.0 010 $a1-4443-4774-8 010 $a1-283-20486-X 010 $a9786613204868 010 $a1-4443-2729-1 010 $a1-4443-2730-5 035 $a(CKB)2670000000059914 035 $a(EBL)644963 035 $a(SSID)ssj0000482368 035 $a(PQKBManifestationID)11308139 035 $a(PQKBTitleCode)TC0000482368 035 $a(PQKBWorkID)10484934 035 $a(PQKB)10389250 035 $a(MiAaPQ)EBC644963 035 $a(PPN)16206876X 035 $a(OCoLC)711779442 035 $a(EXLCZ)992670000000059914 100 $a20100419d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSchizophrenia$b[electronic resource] /$f[edited by] Daniel R. Weinberger, Paul J. Harrison 205 $a3rd ed. 210 $aChichester, West Sussex, UK $cWiley-Blackwell$d2010 215 $a1 online resource (746 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-7697-0 320 $aIncludes bibliographical references and index. 327 $aSchizophrenia; Contents; Contributors; Editor ' s Note; Preface to the 3rd edition; Preface to the First Edition; PART 1: Descriptive Aspects; CHAPTER 1: Concept of schizophrenia: past, present, and future; CHAPTER 2: The schizophrenia construct: symptomatic presentation; CHAPTER 3: Child and adolescent schizophrenia; CHAPTER 4: Late - onset schizophrenia; CHAPTER 5: The schizophrenia spectrum personality disorders; CHAPTER 6: The prodrome of schizophrenia; CHAPTER 7: Course and outcome; CHAPTER 8: Neurocognitive impairments in schizophrenia: their character and role in symptom formation 327 $aPART 2: Biological AspectsCHAPTER 9: The secondary schizophrenias; CHAPTER 10: Schizophrenia: the epidemiological horizon; CHAPTER 11: Environmental risk factors for schizophrenia; CHAPTER 12: Classical genetic studies of schizophrenia; CHAPTER 13: Genetic associations in schizophrenia; CHAPTER 14: Intermediate phenotypes in genetic studies of schizophrenia; CHAPTER 15: Electrophysiology of schizophrenia; CHAPTER 16: Structural brain imaging in schizophrenia and related populations; CHAPTER 17: Functional brain imaging in schizophrenia; CHAPTER 18: Neuropathology of schizophrenia 327 $aCHAPTER 19: Neurodevelopmental origins of schizophreniaCHAPTER 20: Dopamine and schizophrenia; CHAPTER 21: Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia; CHAPTER 22: Animal models of schizophrenia; PART 3: Physical Treatments; CHAPTER 23: Pharmacology and neuroscience of antipsychotic drugs; CHAPTER 24: Principles of pharmacological treatment in schizophrenia; CHAPTER 25: Comparative efficacy and effectiveness in the drug treatment of schizophrenia; CHAPTER 26: Approaches to treatment - resistant patients 327 $aCHAPTER 27: Neurological complications of antipsychotic drugsCHAPTER 28: Metabolic adverse effects associated with antipsychotic medications; PART 4: Psychosocial Aspects; CHAPTER 29: Schizophrenia and psychosocial stresses; CHAPTER 30: Mental health services for patients with schizophrenia; CHAPTER 31: Societal outcomes in schizophrenia; CHAPTER 32: Psychological treatment of psychosis; CHAPTER 33: Economics of the treatment of schizophrenia; Index; colour plates 330 $aSchizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disa 606 $aSchizophrenia 606 $aPsychiatry 615 0$aSchizophrenia. 615 0$aPsychiatry. 676 $a616.89/8 676 $a616.898 701 $aWeinberger$b Daniel R$g(Daniel Roy)$0942476 701 $aHarrison$b P. J$g(Paul J.),$f1960-$01721795 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910831047203321 996 $aSchizophrenia$94121646 997 $aUNINA